There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seattle Genetics (NASDAQ:SGEN) and Heron Therapeutics (NASDAQ:HRTX) with bullish sentiments.
Seattle Genetics (SGEN)
In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Seattle Genetics. The company’s shares closed yesterday at $81.16, close to its 52-week high of $81.66.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 3.0% and a 42.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Jounce Therapeutics Inc, and Acorda Therapeutics.
Seattle Genetics has an analyst consensus of Strong Buy, with a price target consensus of $88.50, a 9.0% upside from current levels. In a report issued on September 24, Leerink Partners also initiated coverage with a Buy rating on the stock with a $101 price target.
.
See today’s analyst top recommended stocks >>
Heron Therapeutics (HRTX)
In a report released yesterday, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on Heron Therapeutics, with a price target of $50. The company’s shares closed yesterday at $31.17.
Folkes wrote:
“: Post a presentation and breakout at the by CEO Barry Quart we are reiterating our Overweight rating and 12-month PT of $50 on HRTX stock. We continue to believe HTX-011 has the potential to be a best-in-class, post-operative, non-opioid pain product with blockbuster potential. We view recent weakness a compelling opportunity to own one of the best fundamental stories in our space at a discounted entry point. Dr. Quart more than adequately addressed recent concerns over the reimbursement landscape, following the omission of a pass-through payment provision from the reconciled House and Senate opioid bill.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.2% and a 38.1% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.
Heron Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
